Dereck D Amakye MBChB DCH FFPM

Oncologist

Extensive pharmaceutical industry experience, with ~20 years in Oncology drug development, spanning translational medicine through late-stage development and life-cycle management. Completed Medical Specialty Training in Pharmaceutical Medicine (Certified Specialist, UK) and Fellow of the Faculty of Pharmaceutical Medicine (FFPM) of Royal Colleges of Physicians. Currently, working as an independent Oncology Drug Development Consultant at DDA Consultancy LLC. Summary of Experiences: Zentalis Pharmaceuticals, Senior Vice-President Clinical Development,- BayerPharmaceuticals, Vice-President ; Head GMA Oncology Pipeline- Novartis Institute of Biomedical Research, Global Clinical Program Leader - AstraZeneca Oncology, UK, Global Brand Physician, Clinical Development - AstraZeneca Oncology Oncology Research Physician, Discovery Medicine- Covance Clinical Research Unit, UK Medical Director Highlight Achievements: • Investigator for ~ 300 phase 1 studies in healthy volunteers over a 6.5-year period at Covance CRU. • Contributed to the development of many agents, which are now approved and marketed drugs, such as: Nplate (Amgen), for treating idiopathic thrombocytopenic purpura; Ramelteon (Takeda), for treating insomnia; Udenafil (Daichii), a phosphodieterase 5 inhibitor, for erectile dysfunction; Exenatide (AstraZeneca) for diabetes mellitus; Tekturna (aliskiren, Novartis), a rennin antagonist, for treating hypertension; Tadalafil (Cialis, Lilly) for erectile dysfunction; Artemether-lumefantrine (Coartem, Novartis) for treating malaria; and Sonidegib (Odomzo, Sun Pharma [Novartis]) for the treatment of locally advance or recurrent BCC. • Honorary Lecturer, University of Leeds (1998-2003) for Certificate in Clinical Research course.